国际衰弱与肌少症研究特别工作组关于ICD - 10对肌少症临床实践及临床试验影响的报告

Implications of ICD-10 for Sarcopenia Clinical Practice and Clinical Trials: Report by the International Conference on Frailty and Sarcopenia Research Task Force.

作者信息

Vellas B, Fielding R A, Bens C, Bernabei R, Cawthon P M, Cederholm T, Cruz-Jentoft A J, Del Signore S, Donahue S, Morley J, Pahor M, Reginster J-Y, Rodriguez Mañas L, Rolland Y, Roubenoff R, Sinclair A, Cesari M

机构信息

Bruno Vellas, MD. Gérontopôle, CHU Toulouse, Service de Médecine Interne et Gérontologie, Clinique, 170 Avenue de Casselardit, 31059 Toulouse, France. Phone: +33 (0) 5 6177-6425; Fax: +33 (0) 6177-6475. Email:

出版信息

J Frailty Aging. 2018;7(1):2-9. doi: 10.14283/jfa.2017.30.

DOI:10.14283/jfa.2017.30

PMID:29412436

Abstract

Establishment of an ICD-10-CM code for sarcopenia in 2016 was an important step towards reaching international consensus on the need for a nosological framework of age-related skeletal muscle decline. The International Conference on Frailty and Sarcopenia Research Task Force met in April 2017 to discuss the meaning, significance, and barriers to the implementation of the new code as well as strategies to accelerate development of new therapies. Analyses by the Sarcopenia Definitions and Outcomes Consortium are underway to develop quantitative definitions of sarcopenia. A consensus conference is planned to evaluate this analysis. The Task Force also discussed lessons learned from sarcopenia trials that could be applied to future trials, as well as lessons from the osteoporosis field, a clinical condition with many constructs similar to sarcopenia and for which ad hoc treatments have been developed and approved by regulatory agencies.

摘要

2016年为少肌症设立ICD - 10 - CM编码是朝着就年龄相关性骨骼肌衰退疾病分类框架的必要性达成国际共识迈出的重要一步。衰弱与少肌症研究国际会议特别工作组于2017年4月召开会议，讨论新编码实施的意义、重要性和障碍，以及加速新疗法开发的策略。少肌症定义与结果联盟正在进行分析，以制定少肌症的定量定义。计划召开一次共识会议来评估这一分析。特别工作组还讨论了少肌症试验的经验教训，这些经验教训可应用于未来的试验，以及骨质疏松领域的经验教训，骨质疏松是一种临床病症，有许多与少肌症相似的结构，并且已经开发出临时治疗方法并获得监管机构的批准。